Q: Which vendors sell Cerebrolysin with independent COA testing?

1 vendor in the Merit Verified directory has independent COA evidence on file for Cerebrolysin — 3 COAs total. COA coverage and test dates are listed on the Cerebrolysin page at https://meritverified.org/peptides/cerebrolysin.

Q: How do I verify the quality of Cerebrolysin from a vendor?

To verify Cerebrolysin quality, look for an independent certificate of analysis (COA) from a third-party lab — not a lab the vendor owns or pays directly. The COA should state the tested compound, lot number, purity percentage (identity and concentration), and the lab's name. Cross-reference the lot number against the vendor's current stock. Merit Verified indexes COAs for Cerebrolysin at https://meritverified.org/peptides/cerebrolysin so you can compare evidence across vendors before buying.

Q: What is the regulatory status of Cerebrolysin?

Cerebrolysin is tracked in the Merit Verified registry. Regulatory status for research peptides in the US has been evolving — the FDA has reclassified a number of peptides out of the 503A compounding ingredient list since 2025. Merit Verified does not provide legal or regulatory advice; check official FDA sources or consult a licensed professional for the current status of Cerebrolysin in your jurisdiction.

Question 1

What is Cerebrolysin?

Accepted Answer

Cerebrolysin is not a single peptide but a complex biologic produced by enzymatic hydrolysis of purified porcine brain tissue, containing low-molecular-weight peptides (<10 kDa) and free amino acids. Manufactured by EVER Pharma (Austria), it is registered in 50+ countries (Europe, Asia, Russia, Latin America) for ischemic stroke, traumatic brain injury, and dementia, but is NOT FDA-approved in the United States. Merit Verified tracks independent COA test results for Cerebrolysin from multiple vendors.

Question 2

Which vendors sell Cerebrolysin with independent COA testing?

Accepted Answer

1 vendor in the Merit Verified directory has independent COA evidence on file for Cerebrolysin — 3 COAs total. COA coverage and test dates are listed on the Cerebrolysin page at https://meritverified.org/peptides/cerebrolysin.

Question 3

How do I verify the quality of Cerebrolysin from a vendor?

Accepted Answer

To verify Cerebrolysin quality, look for an independent certificate of analysis (COA) from a third-party lab — not a lab the vendor owns or pays directly. The COA should state the tested compound, lot number, purity percentage (identity and concentration), and the lab's name. Cross-reference the lot number against the vendor's current stock. Merit Verified indexes COAs for Cerebrolysin at https://meritverified.org/peptides/cerebrolysin so you can compare evidence across vendors before buying.

Question 4

What is the regulatory status of Cerebrolysin?

Accepted Answer

Cerebrolysin is tracked in the Merit Verified registry. Regulatory status for research peptides in the US has been evolving — the FDA has reclassified a number of peptides out of the 503A compounding ingredient list since 2025. Merit Verified does not provide legal or regulatory advice; check official FDA sources or consult a licensed professional for the current status of Cerebrolysin in your jurisdiction.

	Vendor	Price	$/mg	vs avg	Purity	COAs	Merit
🇺🇸	Hydro Research Peptides ✓ verified at source · just now	$0.70· 60mg	$0.01/mg	-99.1%	—	1	91
🇺🇸	Certified Peptides ✓ verified at source · just now	$140· 60mg	$2.33/mg	+82.7%	—	—	62
🇭🇰	zztai Peptide Ltd ✓ verified at source · just now	$68.00· 60mg	$1.13/mg	-11.3%	—	—	43
	optimasupply.is via Disclosed Labs · just now	$69.99· 60mg	$1.17/mg	-8.7%	—	—	Unscored
	peptidetech.is via Disclosed Labs · just now	$74.99· 60mg	$1.25/mg	-2.1%	—	—	Unscored

Cerebrolysin

Pricing for Cerebrolysin

COAs for Cerebrolysin

20 citations indexed for Cerebrolysin

Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability

ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT

ABSTRACT NUMBER: ESOC2026A2077 NEUROD AND NNT1 AS PREDICTORS OF THE OUTCOMES IN ACUTE ISCHEMIC STROKE PATIENTS UNDERGOING MECHANICAL THROMBECTOMY

ABSTRACT NUMBER: ESOC2026A822 VIRTUAL REALITY NEURORREHABILITATION IN ACUTE STROKE PATIENTS AND THE ADD-ON EFFECT OF CEREBROLYSIN

ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE

ABSTRACT NUMBER: ESOC2026A632 CYTOPROTECTIVE EFFICACY OF CEREBROLYSIN IN PATIENTS WITH RESIDUAL POST-THROMBECTOMY PERFUSION DEFICITS: A PROOF-OF-CONCEPT STUDY